Evidence map›Paper›PMID 31745710›Full record

ArticleStem cell reviews and reports2020

Comparison of the Chondrogenic Potential of Mesenchymal Stem Cells Derived from Bone Marrow and Umbilical Cord Blood Intended for Cartilage Tissue Engineering.

Romain Contentin, Magali Demoor, Miranda Concari, Mélanie Desancé, Fabrice Audigié, Thomas Branly, Philippe Galéra

Abstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Romain ContentinUNICAEN, BIOTARGEN, Normandie University, 14000, Caen, France.
Magali DemoorUNICAEN, BIOTARGEN, Normandie University, 14000, Caen, France.
Miranda ConcariUNICAEN, BIOTARGEN, Normandie University, 14000, Caen, France.
Mélanie DesancéUNICAEN, BIOTARGEN, Normandie University, 14000, Caen, France.
Fabrice AudigiéCenter of Imaging and Research on Locomotor Affections in Equines, Ecole Vétérinaire d'Alfort, Université de Paris-Est, 14430, Goustranville, France.
Thomas BranlyUNICAEN, BIOTARGEN, Normandie University, 14000, Caen, France.
Philippe GaléraUNICAEN, BIOTARGEN, Normandie University, 14000, Caen, France. philippe.galera@unicaen.fr.ORCID 0000-0002-7797-2284
Normandie Université · FRÉcole Nationale Vétérinaire d'Alfort · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) remains incurable in humans or horses and mesenchymal stromal/stem cells (MSCs) represent an attractive solution for producing a neocartilage substitute. However, the best MSC source still needs to be identified. This study compared the chondrogenic potential of equine MSCs derived from bone marrow (BM) and umbilical cord blood (UCB), at their undifferentiated status to check if one cell source is better proned, and after chondrogenic-induced differentiation. Chondrogenesis was induced by culture in collagen scaffold with BMP-2 + TGF-ß1 in hypoxia or normoxia. MSCs chondrogenic potential was evaluated using the mRNA and corresponding protein levels for osteogenic, hypertrophic and chondrogenic markers. MSCs characterization demonstrated that BM- and UCB-MSCs differ in proliferation and tripotencies. At undifferentiated status, they also showed differences in their expression of osteogenic, chondrogenic and hypertrophic markers. Upon chondrogenesis induction, both MSCs sources exhibited increased chondrogenic expression and produce an extracellular matrix (ECM) of better quality in hypoxia, although collagen I remained expressed. UCB-MSCs produced higher amounts of collagen II, particularly its IIB isoform, than BM-MSCs, but also collagen I and Htra1, regardless of the oxygen condition. Finally, immunohistochemistry revealed that the BM-MSCs synthesized an ECM of higher quality, regarding the more homogenous distribution of type IIB collagen, compared to UCB-MSCs. Considering collagen I as the major undesirable component in the neo-synthesis of in vitro cartilage, we recommend using BM-MSCs for horse cartilage engineering.

Indexed as

AnimalsBone Morphogenetic Protein 2CartilageCell DifferentiationCell HypoxiaCell ProliferationChondrocytesChondrogenesisCollagen Type ICollagen Type IIExtracellular MatrixFetal BloodHigh-Temperature Requirement A Serine Peptidase 1HorsesHumansMesenchymal Stem CellsBMP2 protein, humanBone Morphogenetic Protein 2Collagen Type ICollagen Type IIHigh-Temperature Requirement A Serine Peptidase 1HTRA1 protein, humanRNA, MessengerTransforming Growth Factor beta1Bone marrowCartilage engineeringChondral defectsChondrocytesChondrogenesisExtracellular matrixHorseMesenchymal stem cellsOsteoarthritisUmbilical cord blood

Identifiers

PMID31745710
OpenAlexW2990708433

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.